Cxcr4 agonist treatment of hematopoietic cells
CA 2405907 A1 · Owner: Salari, Hassan · Inventors: Cashman, Johanne; Clark-Lewis, Ian; Eaves, Connie J.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
In accordance with various aspects of the invention CXCR4 agonists, including , SDF-1 polypeptides and SDF-1 polypeptide homologues may be used in reducing , the rate of hematopoietic cell multiplication. Methods of the invention may comprise administration of an effective amount of an CXCR4 agonist to cells selected from the group consisting of hematopoietic stem cells and hematopoietic progenitor cells. Cells may be treated in vitro or in vivo in a patient. A therapeutically effective amount of the CXCR4 agonist may be administered to a patient in need of such treatment. Patients in need of such treatments may include, for example patients requiring bone marrow or peripheral blood …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed April 12, 2001. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended April 12, 2021.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by April 12, 2023.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.